@article{Gordon Cook_Simona Iacobelli_Anja van Biezen_Dimitris Ziagkos_Veronique LeBlond_Julie Abraham_Grant McQuaker_Stefan Schoenland_Alessandro Rambaldi_Kazimierz Halaburda_Maria Rovira_Simona Sica_Jenny Byrne_Ramon Garcia Sanz_Arnon Nagler_Niels W.C.J. van de Donk_Marjatta Sinisalo_Mark Cook_Nicolaus Kröger_Theo De Witte_Curly Morris_Laurant Garderet_2016, place={Pavia, Italy}, title={High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation}, volume={102}, url={https://haematologica.org/article/view/7934}, DOI={10.3324/haematol.2016.148460}, abstractNote={POEMS syndrome is a rare para-neoplastic syndrome secondary to a plasma cell dyscrasia. Effective treatment can control the disease-related symptom complex. We describe the clinical outcome of autologous stem cell transplantation for patients with POEMS syndrome, determining the impact of patient- and disease-specific factors on prognosis. One hundred and twenty-seven patients underwent an autologous stem cell transplantation between 1997–2010 with a median age of 50 years (range 26–69 years). Median time from diagnosis to autologous stem cell transplantation was 7.5 months with 32% of patients receiving an autologous stem cell transplantation more than 12 months from diagnosis. Engraftment was seen in 97% patients and engraftment syndrome was documented in 23% of autologous stem cell transplantation recipients. Hematologic response was characterized as complete response in 48.5%, partial response in 20.8%, less than partial repsonse in 30.7%. With a median follow up of 48 months (95%CI: 38.3, 58.6), 90% of patients are alive and 16.5% of patients have progressed. The 1-year non-relapse mortality was 3.3%. The 3-year probabilities of progression-free survival and overall survival are 84% and 94%, respectively, with 5-year probabilities of progression-free survival and overall survival of 74% and 89%. In a cohort of graft recipients, detailed organ-specific symptom response demonstrated clear symptom benefit after autologous stem cell transplantation especially in relation to neurological symptom control. The data analyzed in this study demonstrate the clinical utility of autologous stem cell transplantation for patients with POEMS syndrome.}, number={1}, journal={Haematologica}, author={Gordon Cook and Simona Iacobelli and Anja van Biezen and Dimitris Ziagkos and Veronique LeBlond and Julie Abraham and Grant McQuaker and Stefan Schoenland and Alessandro Rambaldi and Kazimierz Halaburda and Maria Rovira and Simona Sica and Jenny Byrne and Ramon Garcia Sanz and Arnon Nagler and Niels W.C.J. van de Donk and Marjatta Sinisalo and Mark Cook and Nicolaus Kröger and Theo De Witte and Curly Morris and Laurant Garderet}, year={2016}, month={Dec.}, pages={160-167} }